Research Analysts Issue Forecasts for Lexeo Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Research analysts at Leerink Partnrs issued their FY2027 earnings per share estimates for shares of Lexeo Therapeutics in a research note issued to investors on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($2.58) per share for the year. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.03) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2028 earnings at $0.12 EPS.

Lexeo Therapeutics Price Performance

NASDAQ LXEO opened at $12.50 on Thursday. Lexeo Therapeutics has a 1-year low of $9.00 and a 1-year high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.21 and a quick ratio of 7.21. The firm has a 50-day moving average of $14.30.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, March 11th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15).

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Blackstone Inc. purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $9,342,000. Omega Fund Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $28,955,000. Finally, Eventide Asset Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $40,298,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.